Immunohistochemical Her-2 1+ means that the immunohistochemical test was found to be negative for Her-2, suggesting that the patient has a better prognosis, but is mostly unable to benefit from targeted anti-Her-2 therapy. Her-2 is one of the immunohistochemical tests, with Her-2 (-) or 1+ being negative for Her-2, Her-2 2+ being inconclusive and requiring further testing by fluorescence in situ hybridization (Fish), and Her-2 3+ being positive for Her-2. Her-2 negative patients have a better prognosis in Luminal type of breast cancer, but mostly fail to benefit from targeted anti-Her-2 therapies, such as trastuzumab, patuximab, etc. Negative immunohistochemistry Her-2 results can provide medical information to clinicians to help make medical decisions, and recommend the relevant patients to choose and apply treatments under the guidance of their doctors.